• Reactive Oxygen Species Assay Kit for FLASH-RT

  2026-08-15

  A translational framework for using DCFH-DA-based live-cell ROS measurements to connect FLASH-RT radiosensitization, oxidative damage, apoptosis, and immune remodeling with decision-ready experimental workflows.

• Cl-Amidine for PAD4 Research Workflows

  2026-08-14

  Cl-Amidine enables controlled interrogation of PAD4-dependent histone citrullination across biochemical, cellular, cancer, autoimmune, and sepsis studies. This workflow-focused guide connects assay design and troubleshooting with the ribotoxic-stress biology of nucleolar Snail1, while clearly separating established evidence from proposed applications.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-08-14

  The reference study identifies a genotype-linked vulnerability in high-grade glioma: ATRX-deficient cells are more sensitive to multi-targeted receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient cells. Its combination data further support evaluating RTK inhibition alongside temozolomide while incorporating ATRX status into preclinical and clinical analyses.

• Biotin (Vitamin B7): Mechanism and Research Use

  2026-08-13

  Biotin, also called Vitamin B7 or Vitamin H, is a coenzyme for carboxylases that support fatty acid synthesis and amino acid metabolism. A8010 provides high-purity biotin for biochemical assays and labeling workflows, but free biotin should not be confused with activated protein-biotinylation reagents.

• MLN4924 HCl Salt and Viral Immune Evasion

  2026-08-13

  A translational framework for using MLN4924 HCl salt to interrogate NAE-dependent protein turnover, cullin-RING ligase biology, and the boundary between cancer and host-pathogen research.

• Nystatin (Fungicidin): Assay Workflows

  2026-08-12

  Build reproducible Candida growth, adhesion, biofilm, and combination assays with Nystatin (Fungicidin), while controlling the solubility challenges of this polyene. A 2024 study also shows how ergosterol modulation can guide more informative Nystatin synergy experiments.

• CTP Solution for High-Integrity mRNA IVT

  2026-08-12

  CTP Solution (100 mM) is a high-integrity Cytidine-5'-triphosphate stock for in vitro transcription and RNA-focused workflows. This article connects nucleotide quality and handling decisions to the design of p21 mRNA–LNP experiments while clarifying what the supporting bladder cancer study does—and does not—demonstrate.

• In Vitro Drug Responses: Arrest Versus Death

  2026-08-11

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response outcomes. The framework supports more rigorous interpretation of anticancer experiments by considering response magnitude, composition, and timing rather than relying on a single viability endpoint.

• UK-5099: A Translational Lens on Immunometabolism

  2026-08-11

  UK-5099 (PF-1005023) offers a focused way to interrogate mitochondrial pyruvate entry in immune and metabolic systems. This thought-leadership guide connects mechanistic biology with standardized whole-blood stimulation, assay design, translational interpretation, and strategic use of MPC inhibition.

• Nebivolol Beyond mTOR: A Translational β1 Lens

  2026-08-10

  Nebivolol hydrochloride offers a precise way to interrogate β1-adrenergic biology while a drug-sensitized yeast study helps define what the compound does not do: inhibit TOR under the tested conditions. This distinction strengthens experimental design across cardiovascular pharmacology research, hypertension research, and heart failure research.

• VX-661: F508del CFTR Corrector Workflow

  2026-08-09

  Build a practical VX-661 workflow that separates CFTR trafficking rescue from channel potentiation, using surface-expression and functional assays side by side. The approach also adapts recent calnexin-dependent variant data to improve cystic fibrosis research, combination studies, and troubleshooting.

• Toremifene for Breast Cancer: 20 Years of Evidence

  2026-08-08

  The reference review synthesizes two decades of clinical and pharmacologic evidence for toremifene, a selective estrogen receptor modulator used in hormone-sensitive breast cancer. Its main contribution is a balanced interpretation of efficacy, safety, pharmacokinetics, and patient-selection considerations rather than a claim of superiority over tamoxifen or aromatase inhibitors.

• Thioguanine Workflows for Cancer and EV71 Studies

  2026-08-07

  Build reproducible 6-thioguanine assays by combining solvent-aware preparation, concentration-response design, and parallel viability controls. The workflow distinguishes cancer cell proliferation inhibition, EV71 virus inhibition, and DNMT1-related hypotheses without treating exploratory data as clinical evidence.

• Dibutyryl-cAMP, Sodium Salt: Advanced Insights in Neuronal R

  2026-08-07

  Explore how Dibutyryl-cAMP, sodium salt enables precision modulation of cAMP signaling in neuronal transdifferentiation and nuclear remodeling. This article delivers unique, evidence-rich perspectives for advanced cAMP pathway research.

• Strategic Use of VX-661 for Variant-Specific CFTR Rescue

  2026-08-06

  This thought-leadership article explores the mechanistic foundations and translational opportunities of VX-661 (F508del CFTR corrector) in cystic fibrosis research. It integrates cutting-edge insights on endoplasmic reticulum proteostasis, calnexin-dependent rescue, and precision workflows, while offering actionable strategic guidance for translational researchers seeking to maximize the impact of CFTR modulator therapies.

8372 records 3/559 page Previous Next 12345 下5页 Last page